Probiomics is a beneficiary of the Lazio Innova “PRE-SEED Plus” grant (PR FESR 2021–2027) for the development of the “Re-Clinic” project.
The Re-Clinic project was created to enable pharmaceutical companies, IRCCS and research centres to access advanced omics analysis services compliant with GCLP standards.
By integrating Proximity Extension Assay (PEA) technology into this workflow, our clients can rely on highly reliable, reproducible data compliant with international regulations, reducing regulatory risks and accelerating access to national and international markets.
The platform enables high-sensitivity multiplex proteomic analyses, with minimal sample consumption and significantly lower cost per marker compared to traditional technologies.
A further competitive advantage is the validation of alternative biological matrices such as saliva and mucus, which opens the door to decentralised studies: sample collection even at home, greater participation, reduced operational costs and improved study retention.
In summary, PROBIOMICS enables its partners to offer next-generation services, combining technological innovation, compliance with international standards and operational flexibility, to transform omics analysis into a concrete and immediately applicable tool.
